3651 results for «328»

Filter By

3651 results

Outcomes after novel transcatheter and surgical tricuspid valve interventions

21 Nov 2021 – From PCR London Valves 2021

Find out more about TRI-SCORE, a new risk score to predict in-hospital mortality after isolated tricuspid valve surgery, 30-day outcomes for transcatheter tricuspid repair from the TriBAND study, both the CLASP TR early feasibility and TRISCEND studies six-month results, and more in this PCR London Valves...

Outcomes after novel transcatheter and surgical tricuspid valve interventions

Emergent transcatheter therapy

21 Nov 2021 – From PCR London Valves 2021

This series of 3 videos presented during the PCR London Valves 2021 Congress allows you to appreciate an emergent mitral ViV implantation after a recent re-do bioprosthetic AVR, a cardiogenic shock after transfemoral mitral valve reconstruction, and MitraClip for torrential mitral regurgitation with Impella CP support.

Emergent transcatheter therapy

Miscellaneous - Paravalvular leak closure, PFO closure and LAA occlusion

21 Nov 2021 – From PCR London Valves 2021

Want to know more about the impact of baseline PFO anatomy on residual right to left shunt after transcatheter closure, transcatheter closure of paravalvular leak, or even percutaneous mitral paravalvular leak closure using CT planning? This PCR London Valves 2021 session is for you!

Miscellaneous - Paravalvular leak closure, PFO closure and LAA occlusion

Unusual situations in valvular interventions

21 Nov 2021 – From PCR London Valves 2021

Let's discover an electrosurgical removal of an entrapped central venous catheter, witness a coronary extra-adventitial hematoma complication of transcatheter tricuspid annuloplasty, and appreciate buddy balloon technique as bailout strategy during RVOT stent embolization, among others, in this special PCR London Valves 2021 session dedicated to unusual...

Unusual situations in valvular interventions

Transcatheter mitral, aortic and pulmonary valve implantation

21 Nov 2021 – From PCR London Valves 2021

Watch this series of videos from PCR London Valves 2021 to learn about acute heart failure hospitalizations following TAVI in the U.S., share a peripheral hospital's experiences with structural valve service modernization, enjoy percutaneous transseptal mitral valve implantation in Brazil, and more!

Transcatheter mitral, aortic and pulmonary valve implantation

PCR London Valves 2021 Hotlines / Late-Breaking Trials: bRIGHT, EXPAND, CHOICE-MI

21 Nov 2021 – From PCR London Valves

Real-world outcomes for tricuspid edge-to-edge repair, predictors of heart failure hospitalisation and its impact on clinical outcomes, one-year outcomes after TMVI... View part of the Late-Breaking Trials presented during PCR London Valves 2021.

PCR London Valves 2021 Hotlines / Late-Breaking Trials: bRIGHT, EXPAND, CHOICE-MI

Predictability at release means better MR outcomes; PASCAL platform significance in a matched analysis

21 Nov 2021 – From PCR London Valves 2021

Join Peter Lüdike and Philipp Lurz to learn more about about the latest study regarding the predictability of mitral regurgitation reduction using the PASCAL device.

Predictability at release

EAPCI: patient initiatives around the world

22 Nov 2021 – From PCR London Valves 2021

In this session, you can find out more about the EAPCI Valve for Life initiative and what progress has been made in selected countries, as well as other collaborative initiatives across the world.

EAPCI:  patient initiatives around the world

30 years of primary PCI – a tale of perseverance

16 May 2023

Over the last 30 years, primary PCI (pPCI) has evolved from an experimental ‘rescue’ intervention to an essential routine procedure – performed daily in cathlabs around the world – which is responsible for saving millions of lives. However, its path to success was far from smooth.

30 years of primary PCI – a tale of perseverance

OPTIMUM: Outcomes of Percutaneous RevascularizaTIon for Management of SUrgically Ineligible Patients with Multivessel or Left Main Coronary Artery Disease

04 Nov 2021

Mirvat Alasnag reviews the OPTIMUM trial, presented by David E. Kandzari, which reports outcomes in a subset of patients who are increasingly seen in modern day catheterization laboratories. It is noteworthy that 1 in 5 patients with left main or multivessel disease are considered surgically ineligible.

Dr. Mirvat Alasnag

Author

Mirvat Alasnag
OPTIMUM: Early Outcomes From a Prospective Registry of PCI in Patients at Prohibitive Risk for CABG

TACSI: Dual or single antiplatelet therapy after CABG in patients with acute coronary syndrome

03 Sep 2025

Aaysha Cader provides her take on TACSI presented by Anders Jeppsson at ESC Congress 2025 in Madrid.

Author

Aaysha Cader
TACSI: Dual or single antiplatelet therapy after CABG in patients with acute coronary syndrome
Didn’t find what you were looking for?